A large number of prestigious academic medical centers offer "executive screening" programs designed to allow asymptomatic people to obtain early risk assessment and detection of cardiovascular disease, presumably with the aim of earlier intervention and more favorable outcomes if an abnormality is identified.
The problem is that indiscriminate screening is not only expensive but runs counter to evidence-based recommendations of medical societies for asymptomatic individuals without specific risk factors, say authors of a research letter published January13 in JAMA Internal Medicine.
"Most of the best and most prestigious cardiology programs in the US have these executive screening programs that charge a lot of money, are not covered by insurance, and have no evidence to back up their value," David Brown, MD, professor of medicine, JohnT. Milliken Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine, St.Louis, told theheart.org| Medscape Cardiology.
"These programs provide an institutional stamp of approval on a two-tier system of medicine: those who can afford to buy whatever they want, and the rest of us who can't afford to do so," he added. "They also make a statement that if someone is willing to pay enough money, they can be given whatever test they want, even if there is no evidence to support it."
In this new analysis, investigators assessed the cardiovascular examinations offered in these programs at 18 "top hospitals" for cardiology and heart surgery, as ranked by US News and World Report, encompassing 28 programs.
They found that the programs included 12 cardiovascular tests plus a resting electrocardiogram (ECG): abdominal aortic ultrasonography; cardiac calcium score; cardiac stress test (including exercise ECG or echocardiography); cardiovascular counseling; carotid artery ultrasonography; carotid intima-media thickness (IMT); coronary artery CT scan; exercise consultation; lipid panel; lipoprotein(a); and vascular screening.
The most commonly offered tests were a lipid panel and cardiac stress testing, offered in 20 of 28 (71%) and 19 of 28 (68%) institutions, respectively. Cardiac CT scans either to determine the calcium score or to visualize the coronary arteries were included in 12 of the 28 programs (43%).
Two programs included cardiovascular counseling and one included exercise consultation.
The lowest-cost program, at $995, was the Comprehensive Health Assessment at Houston Methodist Hospital, while the highest-cost program, which cost $25,000, was the Premier Executive Health Program at Cleveland Clinic.
Only three programs submitted charges to an insurance carrier.
"The premise of using these tests is that the results may help reduce mortality from CVD through earlier disease detection or more precise risk assessment; however, no data support that premise," the authors note, as reflected in guidelines from the American College of Cardiology/American Heart Association (ACC/AHA), the United States Preventive Services Task Force (USPSTF), and the American College of Preventive Medicine (ACPM).
Certain tests or interventions may be recommended under specific circumstances; for example, the USPSTF recommends offering or referring adults who are overweight or obese and have additional cardiovascular risk factors to intensive behavioral counseling interventions for CVD protection.
However, in the current executive screening programs, "a company's CEO who is a marathon runner might get the same testing as a CEO who weighs 300 pounds and is completely sedentary," Brown said.
"There should be no indiscriminate testing where your only qualification is that you have the money to pay for it," he emphasized.
The fact that these are offered at academic medical centers "sends negative messages not only to the public, but also to students, residents, and trainees," putting a "finger in the eye both to the equity of healthcare and to evidence-based medicine at the same time."
And these tests are not without harm, he noted. "There is a downstream cascade effect, where an incidental finding might lead to more tests, then more procedures, and more complications from procedures, and anxiety on the part of the patients."
Commenting on the study fortheheart.org| Medscape Cardiology, Ty Gluckman, MD, medical director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence St.Joseph Health, Portland, Oregon, said that, in "selected circumstances, all of these tests might have clinical value, but from the standpoint of more widespread unselected testing/screening, most of the listed tests have little or no value in asymptomatic individuals, and instead, just drive up costs."
Moreover, unnecessary testing that yields indeterminate findings can prompt further testing that "may also be of little clinical value and potentially engender harm."
He acknowledged that there are anecdotal reports of individuals who were found to have abnormalities on tests, leading to interventions that "saved their lives."
The problem, he said, "is the application of anecdotes to the broader patient population."
He noted that the 2013 ACC/AHA guideline on cardiovascular risk recommends that one's 10-year risk for adverse cardiovascular events (fatal and nonfatal myocardial infarction and stroke) be assessed using an equation that includes demographic factors, blood pressure which, he noted, should be assessed at every physical exam cholesterol levels, diabetic status, and history of tobacco use.
"In short, only one lab value, a cholesterol panel, is suggested for initial cardiovascular risk assessment, and not all of these other tests," he pointed out.
In individuals at intermediate risk, the 2018 AHA/ACC cholesterol guidelines now endorse consideration of using coronary calcium scoring to help further refine the estimated risk if there is uncertainty whether patients should be placed on cholesterol-lowering therapy.
The "flip side of these recommendations is that the current preponderance of evidence doesn't support unselected coronary calcium scoring, unselected stress testing, or unselected carotid ultrasounds to further assess the risk profile of a given individual," said Gluckman, who is also chair of the ACC's Solution Set Oversight Committee (SSOC) and was not involved with the study.
Also commenting for theheart.org| Medscape Cardiology, Rita Redberg, MD, MSc, professor of medicine, University of California, San Francisco, said that "imaging tests with no known benefits, such as offered by the executive screening programs, open a Pandora's box," and "it is hard to put the genie of incidental findings back in the bottle."
It is an "axiom that one (unnecessary) test begets another," said Redberg, who is the editor of JAMA Internal Medicine and the coauthor of an accompanying editorial.
Redberg, who was not involved with the study, said that she "sees many patients in clinic who are losing much sleep and more over meaningless but worrisome incidental findings found on inappropriate imaging tests."
If these programs are to be offered, "patients should be informed accurately and completely of the data on risks and benefits and allowed to decide accordingly," she said.
Brown went further, adding: "There is no need for these programs, which, I think, are done to generate revenue, donations from these wealthy patients.
"You have to show that a screening program prevents people from dying and there is no evidence of that," he said.
No source of funding reported. The study and editorial authors and Gluckman report no relevant financial relationships.
JAMA Intern Med. Published online January13, 2020. Research letter, Editorial
For more Medscape Cardiology news, join us on Facebook and Twitter.
Read this article:
Top Cardiac Centers Offer Unproven 'Executive Screening' - Medscape
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]